Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVALUATION OF THE IMPACT OF A THERAPY MANAGEMENT PLATFORM ON THE MANAGEMENT OF PATIENTS SUFFERING FROM ADVANCED/METASTATIC RENAL CELL CARCINOMA AND RECEIVING FIRST LINE TREATMENT WITH SUNITINIB, VERSUS STANDARD FOLLOW-UP

NCT02187042 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02187042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVALUATION OF THE IMPACT OF A THERAPY MANAGEMENT PLATFORM ON THE MANAGEMENT OF PATIENTS SUFFERING FROM ADVANCED/METASTATIC RENAL CELL CARCINOMA AND RECEIVING FIRST LINE TREATMENT WITH SUNITINIB, VERSUS STANDARD FOLLOW-UP
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
October 7, 2015
Completion date
July 25, 2018
Enrollment
70 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic/advanced renal cell carcinoma